Skip to main content

Table 2 Summary of relative efficacy of adding novel or group 5 interventions to a BR

From: Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany

Intervention Time to SCC Mean treatment effect as Relative Risk RR (SE) Discontinuation rate per month (%) Source/assumption
Bedaquiline vs. placebo 83 days vs. 125 days 2.44 (0.57) 0.87% [14]
Delamanid vs. placebo Not reported (HR of 0.58 reported only for placebo vs. delamanid) 1.73 (0.38) 1.26% Analysis of data reported in [12]
Linezolid vs. placebo 103 days vs. 65 days 1.28 (0.57) 3.1% [13] see main text
  1. BR Background regimen, RR relative risk, SE Standard Error, SCC sputum culture conversion